ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2021
[Treatment of secondary glaucoma following intravitreal anti-VEGF therapy with the XEN® gel stent and mitomycin C].
Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent treatment with intravitreal anti-VEGF (vascular endothelial growth factor) administration can in rare cases lead to secondary glaucoma that is difficult to adjust. The goal of this case series was to analyze the treatment results of the XEN® gel stent in combination with mitomycin C.
methodsThe long-term follow-up over a period of 18 months was evaluated for 3 eyes in 3 patients that underwent treatment with a XEN® gel stent in combination with mitomycin C as a surgical procedure to reduce intraocular pressure.
resultsThe eyes had a baseline pressure of 21-31 mm Hg with 3-5 antiglaucoma medications following 15-25 intravitreal injections. In all 3 eyes a pressure drop of almost 50% to 9-14 mm Hg could be achieved after 18 months with complete discontinuation of all local and systemic medications to reduce intraocular pressure in 2 of the 3 eyes. In 1 eye a choroidal detachment occurred for 2 weeks postoperatively. In another eye a surgical revision of conjunctival penetration was carried out. In two eyes needling was necessary due to scarring. In 2 out of 3 eyes, further intravitreal treatment (9 and 13 respectively) was necessary due to the macular disease but no further increase in intraocular pressure occurred.
conclusionThe XEN® gel stent in combination with mitomycin C is a therapeutic option for difficult to adjust secondary glaucoma following intravitreal anti-VEGF therapy. A continuation of intravitreal anti-VEGF therapy did not lead to a recurrent increase of intraocular pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.